#### Auditory Complications among Childhood Cancer Survivors and Health-1

#### 2 related Quality of Life: A PanCareLIFE study

- 3 Sven Strebel<sup>1,2,3\*</sup>, Katja Baust<sup>4\*</sup>, Desiree Grabow<sup>5</sup>, Julianne Byrne<sup>6</sup>, Thorsten Langer<sup>7</sup>,
- Antoinette am Zehnhoff-Dinnesen<sup>8</sup>, Rahel Kuonen<sup>1,9</sup>, Annette Weiss<sup>1,10</sup>, Tomas Kepak<sup>11</sup>, 4
- Jarmila Kruseova<sup>12</sup>, Claire Berger<sup>13,14</sup>, Gabriele Calaminus<sup>4</sup>, 5
- Grit Sommer<sup>1,15,16\*</sup>, Claudia E. Kuehni<sup>1,17\*\Box ,</sup> and on behalf of the PanCareLIFE Consortium 6
- 7 <sup>1</sup>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
- 8 <sup>2</sup>CANSEARCH research platform in pediatric oncology and hematology, Department of Pediatrics, Gynecology
- 9 and Obstetrics, University of Geneva, Geneva, Switzerland
- 10 <sup>3</sup> Graduate School for Health Sciences, University of Bern, Bern, Switzerland
- 11 <sup>4</sup> Department of Pediatric Hematology and Oncology, University Hospital Bonn, Bonn, Germany
- 12 <sup>5</sup> Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical
- 13 Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg 14 University Mainz, Mainz, Germany
- 15 <sup>6</sup>Boyne Research Institute, Drogheda, Ireland
- 16 <sup>7</sup> Department of Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, 17 Germany
- 18 <sup>8</sup> Department for Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhems University, 19 Münster, Germany
- 20 <sup>9</sup> Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 21 <sup>10</sup> Bavarian Care and Nursing Authority, Amberg, Germany
- 22 <sup>11</sup> University Hospital Brno & International Clinical Research Center (FNUSA-ICRC), Masaryk University, 23 Brno, Czech Republic
- 24 <sup>12</sup> Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and 25 University Hospital Motol, Prague, Czech Republic
- 26 <sup>13</sup> Department of Pediatric Hematology and Oncology, University-Hospital, Saint-Étienne, France
- 27 <sup>14</sup> Lyon University, Jean Monnet University, INSERM, U 1059, Sainbiose, Saint-Étienne, France
- 28 <sup>15</sup> Department of Pediatric Endocrinology, Diabetology and Metabolism, Inselspital, Bern University Children's
- 29 Hospital, University of Bern, Bern, Switzerland
- 30 <sup>16</sup> Department of BioMedical Research, University of Bern, Bern, Switzerland
- 31 <sup>17</sup> Division of Pediatric Hematology/Oncology, Department of Pediatrics, Inselspital, Bern University Hospital,
- 32 University of Bern, Bern, Switzerland
- 33 \*these authors contributed equally; <sup>\vee</sup>Corresponding author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 34 Correspondence to: Claudia E. Kuehni, Prof. MD; Institute of Social and Preventive
- 35 Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland; E-mail:
- 36 claudia.kuehni@ispm.unibe.ch; Telephone: +41 31 684 35 07
- Key words: childhood cancer; survivorship; quality of life; hearing loss; 37
- 38 Tinnitus

#### 39 Abbreviations

BMI	Body Mass Index
BP	Bodily pain
CCS	Childhood cancer survivors
CCSS	American Childhood Cancer Survivor Study
CH	Switzerland
CI	95% Confidence interval
CNS	
CNS Coef.	Central nervous system
	Estimated beta coefficient from linear regression
CRT	Cranial radiation therapy
CZ	The Czech Republic
DE	Germany
FR	France
GH	General health
HRQoL	Health-related quality of life
HSCT	hematopoietic stem cell transplantation
ICCC-3	International Classification of Childhood Cancer, Third edition
IQR	Interquartile range
MCS	Mental component summary
MH	Mental health
PCL	PanCareLIFE
PCS	Physical component summary
PF	Physical functioning
RE	Role emotional
RP	Role physical
SCCSS	Swiss Childhood Cancer Survivor Study
SF	Social functioning
SF-36	Short-Form 36 questionnaire
VT	Vitality

#### 40 ABSTRACT

41	Auditory complications are potential side effects from childhood cancer treatment. Yet,
42	limited evidence exists about the impact of auditory complications-particularly tinnitus-on
43	health-related quality of life (HRQoL) among childhood cancer survivors (CCS). We
44	determined the prevalence of hearing loss and tinnitus in the large European PanCareLIFE
45	cohort of CCS and examined its effect on HRQoL. We included CCS from four European
46	countries who were diagnosed at age $\leq 18$ years; survived $\geq 5$ years; and aged 25–44 years at
47	study. We assessed HRQoL (Short Form 36), hearing loss, and tinnitus using questionnaires.
48	We used multivariable linear regression to examine associations between these two auditory
49	complications and HRQoL adjusting for socio-demographic and clinical factors. Our study
50	population consisted of 6,318 CCS (53% female; median age at cancer diagnosis 9 years
51	interquartile range [IQR] 5–13 years) with median age at survey of 31 years (IQR 28–35
52	years). Prevalence was 7.5% (confidence interval [CI]: 6.9–8.2) for hearing loss and 7.6%
53	(CI: 6.4–9.0) for tinnitus. CCS with hearing loss had impaired physical (coefficient [coef.] -
54	4.3, CI: -7.0 to -1.6) and mental (coef3.2, CI: -5.5 to -0.8) HRQoL when compared with
55	CCS with normal hearing. Tinnitus was also associated with impaired physical (coef8.2, CI:
56	-11.8 to -4.7) and mental (coef5.9, CI: -8.8 to -3.1) HRQoL. We observed the lowest
57	HRQoL among CCS with both hearing loss and tinnitus. Our findings indicate timely
58	treatment of hearing loss and tinnitus may contribute to quality of life of survivors.

3

#### 59 INTRODUCTION

60	Cancer treatment can cause auditory complications, such as hearing loss and tinnitus. <sup>1, 2</sup> In
61	recent surveys, childhood cancer survivors (CCS) reported more hearing loss and tinnitus
62	when compared with their siblings. <sup>3, 4</sup> Ototoxic cancer treatments include platinum-based
63	chemotherapy, cranial radiotherapy (CRT), and surgeries involving the auditory system. <sup>1, 4, 5</sup>
64	Other suspected ototoxic treatments are concomitant medications such as aminoglycosides or
65	loop diuretics, hematopoietic stem cell transplantation (HSCT), or the neurotoxic vinca
66	alkaloid vincristine. <sup>5-7</sup> Hearing loss and tinnitus lead to a wide range of educational and
67	psychosocial problems such as learning difficulties and emotional distress among CCS and
68	the general population. <sup>8-11</sup> The overall burden of auditory complications ultimately affects
69	health-related quality of life (HRQoL) of CCS. <sup>12-14</sup>
70	Only a few studies have investigated auditory complications and how they affect HRQoL
71	among CCS. <sup>12-14</sup> Previous studies with small sample sizes and heterogeneous inclusion
72	criteria make comparisons between studies difficult since findings can only be extrapolated to
73	the overall CCS population to a limited extent. The association of tinnitus with HROOL

the overall CCS population to a limited extent. The association of tinnitus with HRQoL among CCS remains unknown. Several studies examined the prevalence of hearing loss among CCS treated with cisplatin or CRT, yet studies of the overall population—and studies investigating tinnitus—are scarce.<sup>3, 4, 15, 16</sup> We thus combined harmonized data from four

77 European countries into a large cohort of CCS to describe the prevalence of hearing loss and

tinnitus and investigate their association with HRQoL.

#### 79 **METHODS**

## 80 Study population

81	PanCareLIFE (PCL) is a European-based study on late effects among CCS. It focuses on
82	hearing loss, fertility problems, and quality of life. <sup>17, 18</sup> For the current study, we included
83	CCS from Switzerland (CH), Czech Republic (CZ), Germany (DE), and France (FR). The
84	study population included national or regional cohorts of CCS 1) diagnosed with cancer
85	according to the International Classification of Childhood Cancer (ICCC-3), 3rd edition, <sup>19</sup> or
86	Langerhans cell histiocytosis; 2) aged $\leq 18$ years at time of cancer diagnosis; 3) survived $\geq 5$
87	years after cancer diagnosis; 4) were off treatment for cancer at time of study; 5) aged 25-44
88	years when they received the questionnaire. To make data comparable between countries, we
89	restricted our analysis to CCS $\geq$ 25 years and $\leq$ 45 years because data for CCS younger than 25
90	years were unavailable for the German cohort and data for CCS older than 45 years were
91	unavailable for the French cohort. Details about study design, recruitment of participants,
92	country-specific exclusion criteria, and characteristics of different cohorts were published in a
93	separate study protocol. <sup>17</sup>

#### 94 Study procedure

Each country sent questionnaires to their respective regional or national cohorts between 2005 and 2017.<sup>17</sup> The questionnaires were sent by mail except in CZ where clinic staff distributed them during follow-up visits to former patients. The questionnaire included questions about HRQoL, hearing, socio-demographic characteristics, and lifestyle behavior. Non-responders were reminded to complete the questionnaire.<sup>17</sup> Clinical information on

100 cancer diagnosis and treatment was extracted from medical records by each participating101 country.

#### 102 Assessment of HRQoL

We assessed HRQoL with the Short-Form 36 (SF-36) questionnaire.<sup>20</sup> The SF-36 is a 103 widely used instrument: several studies used it to determine HROoL among CCS.<sup>12, 21-24</sup> The 104 questionnaire includes 36 items covering different aspects of physical and mental health 105 106 aggregated into eight health domains: physical functioning (PF, 10 items), role-limitations due to physical problems (RP, 4 items), bodily pain (BP, 2 items), general health (GH, 5 items), 107 108 vitality (VT, 4 items), social functioning (SF, 2 items), role-limitations due to emotional problems (RE, 3 items) and mental health (MH, 5 items).<sup>20, 25</sup> These health domains are 109 further collapsed into summary scores that reflect overall physical and mental health: physical 110 111 component summary (PCS) and mental component summary (MCS). We converted all raw scores into T-scores ranging from 0-100 for each health domain. A higher score indicates 112 better HROoL. The T-scores were further transformed according to reference data from the 113 German norm population stratified for age and sex (mean=50, SD=10).<sup>17, 26</sup> 114

### 115 Auditory complications

We defined self-reported hearing loss (yes, no) and tinnitus (yes, no) as our main determinants of interest for impaired HRQoL. Participating country questionnaires contained slightly different worded questions on hearing (Supplement Table S1). The central PCL data center in Mainz (Germany) aggregated data and harmonized variables between participating countries in 2017.<sup>17</sup> Data on tinnitus (yes, no) were unavailable for the German cohort; thus, we excluded German data for analyses involving tinnitus. We coded missing answers for

- hearing loss (<1%) and tinnitus (5%) as normal hearing and without tinnitus. We assumed
- 123 that CCS with hearing loss or tinnitus would be more likely to answer the question than not
- 124 when compared with CCS without auditory complications.
- 125 Clinical and socio-demographic information

126 Based on previous study findings, we collected clinical and socio-demographic factors

- 127 possibly associated with HRQoL among CCS: sex (female, male); age at survey; migration
- 128 background (yes, no); education (primary, secondary, tertiary); occupational status
- 129 (employed, unemployed); living with a partner (yes, no); currently smoking tobacco (yes, no);
- 130 drinking >1 alcoholic beverage per week (yes, no); body mass index (BMI); cancer diagnosis
- 131 according to ICCC-3<sup>19</sup>; age at diagnosis; history of relapse (yes, no); surgery (yes, no);
- 132 chemotherapy (yes, no); radiotherapy (yes, no); HSCT (yes, no).<sup>12, 21, 23, 27</sup> Respondents self-
- 133 reported age at survey, migration background, education, occupational status, living with a
- 134 partner, tobacco smoking status, alcohol consumption, and BMI variables.<sup>17</sup> Demographic,
- 135 cancer-related, and treatment information were extracted from participating institution
- 136 medical records or corresponding cancer registries.<sup>17</sup>

#### 137 Statistical analysis

We used *t*-tests and fitted multivariable linear regression models to investigate possible associations of hearing loss or tinnitus with HRQoL. First, we examined whether mean scores on SF-36 health domains and PCS and MCS scores differed between CCS with and without auditory complications. We then fitted multivariable linear regression models to investigate whether any possible association of hearing loss or tinnitus with health domains and PCS and MCS scores were explained by clinical or socio-demographic factors. We chose linear

144 regression because HRQoL outcome variables are continuous and binary categorizations of 145 HROoL measured by SF-36 is without consensus in the literature. To mitigate effects of 146 sample imbalances between countries, we standardized cohorts from CZ, DE, and FR 147 according to age at survey and sex variables. Because of the balanced distribution across all 148 age groups and genders, we used the CH cohort as the reference population to calculate 149 appropriate weights. Based on the conceptual framework of directed acyclic graphs (Supplement Figure S1),<sup>28</sup> we adjusted our models for the following co-variables: age at 150 survey (continuous in years); age at cancer diagnosis (continuous in years); type of cancer 151 (categorical according ICCC-3); history of relapse (yes, no); surgery (yes, no); chemotherapy 152 (yes, no); radiotherapy (yes, no); and HSCT (yes, no). We decided to include country of data 153 provider to adjust for country-specific differences in recruitment of study participants and 154 audiological monitoring.<sup>17, 29, 30</sup> We calculated global *p*-values using the Wald test. 155 Since we hypothesized the burden of auditory complications may be largest when both 156

tinnitus and hearing loss are present,<sup>31</sup> we performed a sub-analysis to further investigate a
potential causal relationship between auditory complications and HRQoL. We coded auditory
complications as either 1) no auditory complications; 2) hearing loss only; 3) tinnitus only; or
4) hearing loss and tinnitus.

161 We used Stata version 16.1 (StataCorp LP, Austin, Texas) for all analyses.

### 162 **RESULTS**

## 163 Characteristics of study population

- 164 In total, 6,318 CCS were available for our analysis. Of the 6,318 CCS, most were from DE
- 165 (n = 4,650; 74%); 822 (13%) from CH; 592 (9%) from CZ; and 254 (4%) from FR (Table 1).
- 166 Our study population included 3,326 (53%) females and 2,992 (47%) males with median age
- 167 of 31 (interquartile range [IQR] 28-35 years) at survey, median age 9 (IQR 5-13 years) at
- 168 cancer diagnosis, and median 23 years (IQR 19-28) since cancer diagnosis. Leukemias (n =
- 169 2,033; 32%), lymphomas (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (CNS) tumors (n = 1,466; 23%), and central nervous system (n = 1,466; 24%), and central nervous sy
- 170 892; 14%) were most common cancer diagnoses. CCS received cancer treatment by surgery
- 171 (2,580; 41%); chemotherapy (5,070; 80%); and radiotherapy (3,092; 49%).

## 172 Prevalence of auditory complications after childhood cancer

Of participating CCS, 7.5% (476/6,318; CI: 6.9-8.2) reported hearing loss. Data on tinnitus 173 174 was available for the cohorts from CH, CZ, and FR resulting in a combined cohort of 1,668 CCS. Of those, 7.6% (127/1.668; CI: 6.4-9.0) reported tinnitus. Among CCS with tinnitus (n= 175 176 127), 45 (35%) also reported hearing loss. CCS diagnosed with CNS tumors, neuroblastoma, 177 hepatic tumors, malignant bone tumors, soft tissue sarcomas, germ cell tumors, and epithelial 178 neoplasms reported hearing loss more often than CCS diagnosed with leukemia (all p < p179 0.001) (Figure 1). CCS of hepatic tumors had the highest prevalence of hearing loss (8/28; 180 28.6%, CI: 13.2-48.7) followed by malignant bone tumors (91/378; 24.1%, CI: 19.8-28.7) and 181 CNS tumors (130/892; 14.6%, CI: 12.3-17.1). Tinnitus prevalence was highest among CCS 182 diagnosed with malignant bone tumors (16/103; 15.5%, CI: 9.1-24.0) and CNS tumors 183 (33/255; 12.9%, CI: 9.1-17.7) (Figure 2).

#### 184 Association of auditory complications with HRQoL

- 185 CCS with hearing loss had lower HRQoL mean scores than CCS with normal hearing (all
- 186 differences with p < 0.001) (Figure 3A). Looking at SF-36 summary scores, CCS with hearing
- 187 loss scored 45.3 in overall physical (PCS) and 46.0 in overall mental (MCS) HRQoL. In
- 188 comparison, CCS with normal hearing had 51.7 for PCS and 50.0 for MCS scores. Among the
- 189 eight health domains, we observed the largest mean differences between CCS with and
- 190 without hearing loss in physical functioning (40.6 vs. 48.3), general health (45.1 vs. 50.9), and
- 191 social functioning (43.0 vs. 48.2).
- 192 CCS with tinnitus scored lower than CCS without tinnitus in all health domains and PCS
- 193 (42.7 vs. 52.2) and MCS (43.1 vs. 49.9) summary scores (all differences with p < 0.001)

194 (Figure 3B). The largest mean differences between CCS with and without tinnitus were again

in physical functioning (40.2 vs. 48.9), general health (41.6 vs. 51.0), and social functioning

196 (39.7 vs. 48.3).

In the multivariable linear regression, hearing loss remained associated with lower HRQoL 197 198 scores after adjusting for socio-demographic and cancer-related factors (Table 2). For PCS, 199 coef. were -4.3 (CI: -7.0 to -1.6) among those with hearing loss and -3.2 (CI: -5.5 to -0.8) for 200 MCS. On average, overall physical or mental HROoL was reduced by 4.3 or 3.2 points for 201 CCS with hearing loss compared with CCS with normal hearing. The association was strongest for general health, followed by physical functioning, vitality, and social functioning 202 203 (coef. ranging from -4.6 to -3.8, p < 0.05) (Table 2). We observed borderline or no associations 204 of hearing loss in role physical and role emotional.

- 205 Tinnitus also remained associated with lower HRQoL scores in multivariable linear
- regression (Table 2). The effects of tinnitus on PCS (coef. -8.2, CI: -11.8 to -4.7) and MCS
- 207 (coef. -5.9, CI: -8.8 to -3.1) were greater compared with the effects of hearing loss (coef. of -
- 4.3 for PCS and -3.2 for MCS). We found the strongest effect of tinnitus on vitality (coef. -
- 209 8.4, CI: -11.3 to -5.6), general health (coef. -8.3, CI: -11.4 to -5.3), and social functioning
- 210 (coef. -7.9, CI: -11.0 to -4.7) (all p < 0.001).
- 211 We found CCS with both tinnitus and hearing loss had lower overall physical and mental
- 212 HRQoL compared with CCS with hearing loss alone (coef. -14.5 vs. -0.6 for PCS and coef. -
- 213 5.0 vs. -2.9 for MCS) (Table 3). When compared with tinnitus alone, the effect of hearing loss
- and additional tinnitus was also larger for overall physical HRQoL (coef. -5.4 vs. -14.5 for
- 215 PCS), yet similar for overall mental HRQoL (coef. -6.8 vs. -5.0 for MCS).

#### 216 **DISCUSSION**

217	We found the prevalence of auditory complications varied between cancer diagnoses and
218	the highest prevalence of hearing loss and tinnitus among survivors of CNS and malignant
219	bone tumors. HRQoL was lower among CCS with auditory complications than for those with
220	normal hearing. Hearing loss and tinnitus were strongly associated with physical functioning,
221	vitality, general health, and social functioning. We observed lower HRQoL among CCS with
222	hearing loss and additional tinnitus compared with CCS with hearing loss alone.

#### 223 Strengths and limitations

224 Since our study is the largest cohort of CCS to examine auditory complications and their 225 association with HRQoL, it results in high statistical power and good representativeness 226 because it combined data from population-based and regional well-defined cohorts. Tinnitus 227 is more frequent among CCS compared with the general population,<sup>2</sup> yet its association with HRQoL among CCS was unknown. We included CCS with all possible cancer treatments, not 228 only those exposed to ototoxic treatments such as platinum-based chemotherapy or CRT, 229 230 which allowed assessing the burden of auditory complications among the overall population of CCS.<sup>32</sup> We applied SF-36—an established and validated instrument widely used in 231 232 previous studies—to measure HRQoL among CCS, which allows comparing our data with other studies.<sup>21-23, 27, 33, 34</sup> Data from participating countries were collected centrally and 233 234 harmonized before merging to avoid data management errors.<sup>17</sup> However, our study results might still be influenced by study design differences of participating countries, leading to 235 potential selection bias. For example, FR did not contact CCS of leukemias, and-similar to 236 237 DE—sent questionnaires later ( $\geq 10$  years) than CH and CZ (both  $\geq 5$  years) after cancer

diagnosis.<sup>17</sup> Considering the French cohort represents only 4% of the total study population, 238 239 we assume that selection based on cancer diagnosis did not result in a major bias in our 240 findings. Additionally, time since diagnosis was investigated in two larger population-based studies showing either no or minor effects on HRQoL among CCS.<sup>23, 27</sup> Other limitations 241 242 relate to the main exposures of interest; hearing loss and tinnitus. Since auditory 243 complications were assessed by questionnaire and dependent on severity, underreporting is 244 possible. For instance, CCS with severe hearing loss possibly received better audiologic care and recall it better than CCS with mild high-frequency hearing loss who are unaware of it.<sup>35</sup> 245 Additionally, SF-36 does not specifically measure HRQoL related to hearing and may not 246 capture life situations affected by auditory complications 247

#### 248 Comparison with previous studies

Among our study population, 7.5% of CCS reported hearing loss. We observed particularly 249 high prevalence among survivors of hepatoblastoma, CNS tumors, and malignant bone 250 tumors—an expected finding from higher cisplatin or CRT use compared with other cancer 251 treatment regimes.<sup>5, 7</sup> Larger studies on hearing loss prevalence among CCS mostly focused 252 on high-risk populations treated with platinum-based chemotherapy or CRT.<sup>5-7</sup> Two 253 254 population-based studies from Switzerland (Swiss Childhood Cancer Survivor Study; 255 SCCSS) and the United States (Childhood Cancer Survivor Study; CCSS) determined the prevalence of hearing loss among the overall CCS population with questionnaires.<sup>3, 16</sup> The 256 Swiss population in our cohort overlaps with the study population of the SCCSS.<sup>3, 17, 36</sup> 257 Therefore, we only compared our data with the CCSS study.<sup>16</sup> Whelan and colleagues found a 258 prevalence of self-reported hearing loss of 5%, which is slightly lower than what we found 259 (7.5%).<sup>16</sup> They included CCS diagnosed in earlier years (1970-1986) compared with our study 260

(1974-2009), which possibly explains the difference. Considering cisplatin was first approved
in 1978 for adult cancer treatment, it is possible a higher proportion of CCS in our cohort
were treated with ototoxic platinum-based chemotherapy, as Weiss and colleagues also
discuss in their SCCSS study.<sup>3, 37</sup>

The prevalence of tinnitus was 7.6% among our study population. CCS diagnosed with 265 CNS tumors or malignant bone tumors had a three to four times higher prevalence compared 266 with survivors of leukemias. The higher prevalence is possibly explained by previously 267 identified risk factors for tinnitus among CCS, such as exposure to cisplatin, CRT, and CNS 268 surgeries.<sup>4</sup> In Meijer and colleagues' systematic review, the prevalence of tinnitus ranged 269 from 3-17%.<sup>2</sup> They also recently published a population-based study where they estimated the 270 prevalence of tinnitus to be 9.5% among CCS compared with 3.7% for siblings.<sup>4</sup> Their 271 272 findings are consistent with our study.

Audiological complications were associated with lower HRQoL, particularly with 273 decreased physical functioning, general health, vitality, and social functioning. Physical 274 functioning reflects limitations in physical activities, such as difficulties walking a mile or 275 exercising vigorously due to health problems.<sup>20</sup> In a SCCSS study, physical well-being was 276 lower among younger CCS with hearing loss than for CCS with normal hearing.<sup>12</sup> General 277 278 health reflects current and future health perceptions; for example, how people perceive their 279 health when compared with peers or whether their health deteriorates in the future.<sup>20</sup> General 280 health was also heavily impaired among CCS when compared with siblings or the general population in previous studies.<sup>23, 27</sup> The SF-36 assesses vitality with questions such as whether 281 people feel full of energy or tired and worn out.<sup>20</sup> Previous studies of the general population 282 showed-depending on severity-patients with tinnitus experience comorbidities, such as 283

284	sleep disturbance, fatigue, and depression. <sup>10, 11, 38</sup> Hearing loss possibly leads to feelings of
285	fatigue from long periods of effortful listening. <sup>39-41</sup> Impaired social functioning refers to
286	limitations in social activities, such as visiting family and friends, due to physical or
287	emotional health problems. <sup>20</sup> CCS with hearing loss reported psychosocial difficulties and
288	communication problems in previous studies examining the impact of hearing loss on
289	HRQoL. <sup>12-14</sup> Yet, a direct comparison with our study remains difficult because they only
290	included children and adolescents—a study population whose social behavior differs from our
291	adult study population (median age 31 at survey). Data from adult CCS participating in the St.
292	Jude Lifetime Cohort Study showed treatment-related hearing loss associated with reduced
293	social attainment, which possibly relates to decreased social engagement. <sup>42</sup> However, none of
294	these studies investigated the impact of tinnitus on social behavior and attainment.

# 295 Causality between auditory complications and HRQoL

The observed association of lower vitality and social functioning possibly relates to 296 educational and psychosocial problems caused by auditory complications.<sup>8, 10, 11, 13</sup> Other 297 chronic health problems, such as musculoskeletal or neurological, also affect HRQoL.<sup>27</sup> In our 298 299 study, we could not adjust for other chronic health problems. Since the risk of auditory 300 complications and other chronic health problems increases with more intensive cancer 301 treatment, unobserved late effects in other organ systems could contribute to lower physical and mental HRQoL (Supplement Figure S1).<sup>4, 5, 7, 43, 44</sup> However, we observed hearing loss 302 303 with additional tinnitus reduces HRQoL more than hearing loss alone. Since we assumed the 304 burden on daily life is greater when CCS experience both hearing loss and tinnitus, it possibly indicates a causal relationship.<sup>31</sup> Interestingly, tinnitus alone also had a greater impact on 305 306 HRQoL than hearing loss alone. Since data are self-reported and tinnitus is probably

307 underreported in our study, further research using objective hearing tests and validated

308 instruments to assess tinnitus are important to understand its impact on CCS.<sup>30, 45</sup>

#### 309 Conclusion

Our study showed hearing loss and tinnitus strongly affected HRQoL among CCS—
particularly reduced HRQoL among survivors with both, hearing loss and tinnitus. Our
findings support current guideline recommendations for timely referrals to audiologists for

313 tinnitus symptoms and optimized treatment of hearing loss and tinnitus since both affect

314 HRQoL.<sup>30</sup>

#### 315 AUTHORS CONTRIBUTIONS

SST and KB are the first authors of this paper and both contributed substantially to this 316 work. SST prepared the final data set, wrote the manuscript, performed the data analysis and 317 interpretated the results. KB coordinated the study, contributed to the design, implementation, 318 319 data collection and harmonization, data preparation, reviewed the manuscript, and commented 320 on data analysis and interpretation. DG and JB were part of the PanCareLIFE coordination 321 team and contributed to the implementation and coordination of the study; they also 322 supervised collection, and harmonization and maintenance of data. TL and AaZD contributed 323 to the study implementation and to data harmonization and they provided their medical expertise for data analysis and interpretation. RK, AW, TK, JK, CB conducted the study in 324 325 the different countries and contributed to data collection and harmonization. AW was 326 involved in the study design. GC supervised the design, implementation and coordination of 327 the study, and contributed to data collection, harmonization and analysis. GS and CK are 328 senior authors of the study; they were involved in the study design and implementation, in

- 329 collection, harmonization, and maintenance of data, they supervised analysis and
- interpretation of data and reviewed the manuscript. All co-authors provided feedback on the
- 331 manuscript and approved its final version.

#### 332 ACKNOWLEDGMENTS

We thank all survivors of childhood and adolescent cancers and their families for theirparticipation in our study.

335 PanCareLIFE (Grant no. 602030) is a collaborative project in the 7th Framework Program 336 of the European Union. Project partners are Universitätsmedizin der Johannes Gutenberg-337 Universität Mainz, Germany (PD Dr P Kaatsch, Dr D Grabow); Boyne Research Institute, 338 Drogheda, Ireland (Dr J Byrne, Ms H Campbell); Pintail Ltd., Dublin, Ireland (Mr C Clissmann, Dr K O'Brien); Academisch Medisch Centrum bij de Universiteit van 339 Amsterdam, the Netherlands (Prof Dr LCM Kremer); Universität zu Lübeck, Germany (Prof 340 341 T Langer); Stichting VU-VUMC, Amsterdam, the Netherlands (Dr E van Dulmen-den Broeder, Dr MH van den Berg); Erasmus Universitair Medisch Centrum, Rotterdam, the 342 Netherlands; and Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands 343 (Prof Dr MM van den Heuvel-Eibrink); Charité-Universitätsmedizin Berlin, Germany (Prof 344 345 Dr A Borgmann-Staudt); Westfälische Wilhelms-Universität Münster, Germany (Prof Dr A 346 am Zehnhoff-Dinnesen); Universität Bern, Switzerland (Prof Dr CE Kuehni); Istituto Giannina Gaslini, Genoa, Italy (Dr R Haupt); Fakultni nemocnice Brno, Czech Republic (Dr 347 348 T Kepak); Centre Hospitalier Universitaire Saint-Étienne, Saint-Étienne, France (Dr C 349 Berger); Kraeftens Bekaempelse, Copenhagen, Denmark (Dr JF Winther); Fakultni 350 nemocnice v Motole, Prague, the Czech Republic (Dr J Kruseova); Universitaetsklinikum

351 Bonn, Bonn, Germany (Dr G Calaminus, K Baust); and University Hospital Essen, Essen,

352 Germany (Prof U Dirksen). The EU Commission takes no responsibility for any use made of

353 the information set out.

354 In Switzerland, we thank the Swiss Childhood Cancer Survivor Study team, the Swiss

355 Paediatric Oncology Group data managers, and the Swiss Childhood Cancer Registry study

team. We also thank Marcel Zwahlen for statistical advice. We thank the editorial service of

357 the Institute of Social and Preventive Medicine at the University of Bern for the editorial

358 suggestions.

359 In Czech Republic, at the University Hospital of Brno we thank the team of collaborators

360 from the Children's Hospital in Brno, Masaryk University in Brno, especially Katerina

361 Kepakova, and Brno survivors' association Together Toward a Smile: H Hrstková, V

362 Bajčiová, D Hošnová, Z Kuttnerová, M Blanářová, R Mazúr, I Mikulec, E Bučková, L

363 Červinková, E Bařinová, I Krupková, E Novotná, P Chloupková, Z Wimmerová, L Štrublová,

and many other external collaborators and supporters.

365 At the University Hospital of Prague LTFU Care Registry, the authors thank the team of

366 the Prague Childhood Cancer Survivor Study: Aleš Lukš, P Keslová, M Ganevová, V

367 Reichlová, J Bašeová, L Nováková, M Douchová, and M Čepelová.

368 In France, we thank the team of the long-term follow-up study (SALTO): Faure-Conter

369 (Lyon), N Corradini (Lyon), D Plantaz (Grenoble), E Tarral (Grenoble), I Durieu (Lyon), I

370 Guichard (Saint-Étienne), L Casagranda and F Odier (Saint-Étienne), N Gauthier (Lyon), P

371 Métral (Lyon), M Mercier (Lyon), S Billet (Grenoble), C Celette (Grenoble), I Schiff

372 (Grenoble), and A Loubier (Saint-Étienne).

373	In Germany, we thank the team of the Clinic of Phoniatrics and Pedaudiology at the
374	University Hospital in Münster and theVIVE group and members of the GCCR: U Creutzig
375	(Hannover), T Langer (Lübeck), J Dobke (Berlin), I Jung (Mainz), I Kerenyi (Mainz), C
376	Teske (Bonn), and M Zimmermann (Hannover). In Germany, they also thank the team at
377	GCCR in its role as central data center for PanCareLIFE (Peter Kaatsch, Claudia Spix,
378	Melanie Kaiser, Claudia Bremensdorfer).
379	Our project received funding from the European Union's Seventh Framework Program for
380	research, technological development, and demonstration under Grant no. 602030.
381	In Switzerland, our project received funding from the Swiss Cancer League (Grant no.
382	KLS-3412-02-2014, KLS-3886-02-2016, and HSR-4951-11-2019), the Swiss Cancer
383	Research Foundation (Grant no. KFS-4157-02-2017), the Bernese Cancer League,
384	Kinderkrebshilfe Schweiz, Kinderkrebs Schweiz, and the CANSEARCH Foundation
385	(https://cansearch.ch/en/). The work of the SCCR was supported by the Swiss Pediatric
386	Oncology Group, Schweizerische Konferenz der kantonalen Gesundheitsdirektorinnen und -
387	direktoren, the Swiss Cancer Research, Kinderkrebshilfe Schweiz, Bundesamt für Gesundheit,
388	National Institute for Epidemiology and Cancer Registration, and Celgene.
389	In the Czech Republic, our study received funding from the University Hospital of Brno
390	from the Ministry of Education, Youth and Sports of the Czech Republic, under Grant no.
391	7E13061 and the University Hospital of Prague from the foundation Národ dětem.

In France, our study received funding from The Wyeth Foundation, the French NationalInstitute of Cancer (INCa), and the French League against Cancer.

In Germany, our study received funding from the German Cancer Aid (Grant No. 110298).

- 395 Data for this subproject were provided by University of Bern, Switzerland (Prof CE
- 396 Kuehni); Fakultni nemocnice Brno, Czech Republic (Dr T Kepak); Centre Hospitalier
- 397 Universitaire Saint-Étienne, France (Dr C Berger); Fakultni nemocnice v Motole, Prague,
- 398 Czech Republic (Dr J Kruseova); and Universitaetsklinikum Bonn, Bonn, Germany (Dr G
- 399 Calaminus).
- 400 Prof Dr NW Paul at the University of Mainz and Prof Dr Lisbeth E Knudsen from the
- 401 University of Copenhagen provided independent ethics advice.

## 402 CONFLICT OF INTEREST STATEMENT

403 The authors declare that there is no conflict of interest.

## 404 DATA AVAILABILITY STATEMENT

The data that support the information of this manuscript were accessed on secured servers of the Institute of Social and Preventive Medicine at the University of Bern. Individual-level sensitive data can only be made available for researchers who fulfil the respective legal requirements. All data requests should be communicated to the corresponding author.

# 409 ETHICS STATEMENT

- 410 PanCareLIFE is a multinational collaborative research project that has harmonized and
- 411 combined data from regional and national cohorts across Europe. Data collection and analysis
- 412 for each cohort was approved by the responsible ethics committee in each participating

- 413 country. For Germany this is the Ethics Committee of the Medical Association of Westphalia-
- 414 Lippe and the Medical faculty of the Westphalian Wilhelms University (2012-530-f-S), for
- 415 Switzerland the Cantonal Ethics Committee of the Canton of Bern (KEK-BE: 166/2014;
- 416 2021-01462), for the Czech Republic the Ethics Committee for Multi-Centric Clinical Trials
- 417 of the University Hospital Motol (EK-1723/13) and the Multi-Centric Ethics Committee of
- 418 the University Hospital Brno (approval date: 2014/10/22), and for France the Personal
- 419 Protection Committee South East 1 (CPP: 2015-23).

#### 420 **REFERENCES**

421 1. Landier W. Ototoxicity and cancer therapy. Cancer 2016;122:1647-58.

422 2. Meijer AJM, Clemens E, Hoetink AE, van Grotel M, van den Heuvel-Eibrink MM.
423 Tinnitus during and after childhood cancer: A systematic review. Critical reviews in
424 oncology/hematology 2019;135:1-7.

3. Weiss A, Sommer G, Kasteler R, Scheinemann K, Grotzer M, Kompis M, Kuehni
CE. Long-term auditory complications after childhood cancer: A report from the Swiss
Childhood Cancer Survivor Study. Pediatric blood & cancer 2017;64:364-73.

428 4. Meijer AJM, Fiocco MF, Janssens GO, Clemens E, Tissing WJE, Loonen JJ, van
429 Dulmen-den Broeder E, de Vries ACH, Bresters D, Versluys B, Ronckers CM, Kremer LCM,
430 et al. Risk factors associated with tinnitus in 2948 Dutch survivors of childhood cancer: a

431 Dutch LATER questionnaire study. Neuro-oncology advances 2020;2:vdaa122.

5. Strebel S, Mader L, Sláma T, Waespe N, Weiss A, Parfitt R, Am ZehnhoffDinnesen A, Kompis M, von der Weid NX, Ansari M, Kuehni CE. Severity of hearing loss
after platinum chemotherapy in childhood cancer survivors. Pediatric blood & cancer
2022;69:e29755.

6. Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ,
Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, van der Pal HJ,
van Grotel M, et al. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of
childhood cancer: A DCOG late-effects study. European journal of cancer (Oxford, England :
1990) 2016;69:77-85.

7. Moke DJ, Luo C, Millstein J, Knight KR, Rassekh SR, Brooks B, Ross CJD, Wright
M, Mena V, Rushing T, Esbenshade AJ, Carleton BC, et al. Prevalence and risk factors for

443 cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional
444 North American cohort study. The Lancet. Child & adolescent health 2021;5:274-83.

8. Bass JK, Liu W, Banerjee P, Brinkman TM, Mulrooney DA, Gajjar A, Pappo AS,
Merchant TE, Armstrong GT, Srivastava D, Robison LL, Hudson MM, et al. Association of
Hearing Impairment With Neurocognition in Survivors of Childhood Cancer. JAMA
oncology 2020;6:1363-71.

9. Orgel E, O'Neil SH, Kayser K, Smith B, Softley TL, Sherman-Bien S, Counts PA,
Murphy D, Dhall G, Freyer DR. Effect of Sensorineural Hearing Loss on Neurocognitive
Functioning in Pediatric Brain Tumor Survivors. Pediatric blood & cancer 2016;63:527-34.

452 10. Langguth B. A review of tinnitus symptoms beyond 'ringing in the ears': a call to

453 action. Current medical research and opinion 2011;27:1635-43.

454 11. Bhatt JM, Bhattacharyya N, Lin HW. Relationships between tinnitus and the
 455 prevalence of anxiety and depression. The Laryngoscope 2017;127:466-69.

456 12. Weiss A, Sommer G, Schindera C, Wengenroth L, Karow A, Diezi M, Michel G,
457 Kuehni CE. Hearing loss and quality of life in survivors of paediatric CNS tumours and other

458 cancers. Quality of life research : an international journal of quality of life aspects of 459 treatment, care and rehabilitation 2019;28:515-21.

460 13. Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML. Hearing
 461 loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report

462 from the Children's Oncology Group. Pediatrics 2007;120:e1229-36.

463 14. Rajput K, Edwards L, Brock P, Abiodun A, Simpkin P, Al-Malky G. Ototoxicity464 induced hearing loss and quality of life in survivors of paediatric cancer. International journal
465 of pediatric otorhinolaryngology 2020;138:110401.

466 15. van As JW, van den Berg H, van Dalen EC. Platinum-induced hearing loss after
467 treatment for childhood cancer. The Cochrane database of systematic reviews
468 2016;2016:Cd010181.

16. Whelan K, Stratton K, Kawashima T, Leisenring W, Hayashi S, Waterbor J, Blatt
J, Sklar CA, Packer R, Mitby P, Robison LL, Mertens AC. Auditory complications in
childhood cancer survivors: a report from the childhood cancer survivor study. Pediatric blood
& cancer 2011;57:126-34.

473 17. Calaminus G, Baust K, Berger C, Byrne J, Binder H, Casagranda L, Grabow D,
474 Grootenhuis M, Kaatsch P, Kaiser M, Kepak T, Kepáková K, et al. Health-Related Quality of
475 Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE.
476 DEED A 10 21051

476 JMIR research protocols 2021;10:e21851.

perpetuity.	•
It is made available under a CC-BY	4.0 International license .

477	18. Byrne J, Grabow D, Campbell H, O'Brien K, Bielack S, Am Zehnhoff-Dinnesen
478	A, Calaminus G, Kremer L, Langer T, van den Heuvel-Eibrink MM, van Dulmen-den
479	Broeder E, Baust K, et al. PanCareLIFE: The scientific basis for a European project to
480	improve long-term care regarding fertility, ototoxicity and health-related quality of life after
481	cancer occurring among children and adolescents. European journal of cancer (Oxford,
482	England : 1990) 2018;103:227-37.

- 483 19. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification
  484 of Childhood Cancer, third edition. Cancer 2005;103:1457-67.
- 485 20. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36).
  486 I. Conceptual framework and item selection. Medical care 1992;30:473-83.

487 21. Reulen RC, Winter DL, Lancashire ER, Zeegers MP, Jenney ME, Walters SJ,
488 Jenkinson C, Hawkins MM. Health-status of adult survivors of childhood cancer: a large489 scale population-based study from the British Childhood Cancer Survivor Study. International
490 journal of cancer 2007;121:633-40.

- 22. Reulen RC, Zeegers MP, Jenkinson C, Lancashire ER, Winter DL, Jenney ME,
  Hawkins MM. The use of the SF-36 questionnaire in adult survivors of childhood cancer:
  evaluation of data quality, score reliability, and scaling assumptions. Health and quality of life
  outcomes 2006;4:77.
- 23. van Erp LME, Maurice-Stam H, Kremer LCM, Tissing WJE, van der Pal HJH, de
  Vries ACH, van den Heuvel-Eibrink MM, Versluys BAB, Loonen JJ, Bresters D, Louwerens
  M, van der Heiden-van der Loo M, et al. Health-related quality of life in Dutch adult
  survivors of childhood cancer: A nation-wide cohort study. European journal of cancer
  (Oxford, England : 1990) 2021;152:204-14.
- 24. Penson A, Walraven I, Bronkhorst E, Maurice-Stam H, Grootenhuis MA, Van der
  Heiden-van der Loo M, Tissing WJE, Van der Pal HJH, De Vries ACH, Bresters D, Ronckers
  C, Van den Heuvel MM, et al. The Impact of Cancer-Related Fatigue on HRQOL in
  Survivors of Childhood Cancer: A DCCSS LATER Study. Cancers 2022;14.

504 25. Roser K, Mader L, Baenziger J, Sommer G, Kuehni CE, Michel G. Health-related 505 quality of life in Switzerland: normative data for the SF-36v2 questionnaire. Quality of life 506 research : an international journal of quality of life aspects of treatment, care and 507 rehabilitation 2019;28:1963-77.

- 508 26. Ellert U, Bellach BM. [The SF-36 in the Federal Health Survey--description of a
  509 current normal sample]. Gesundheitswesen (Bundesverband der Arzte des Offentlichen
  510 Gesundheitsdienstes (Germany)) 1999;61 Spec No:S184-90.
- 511 27. Rueegg CS, Gianinazzi ME, Rischewski J, Beck Popovic M, von der Weid NX,
  512 Michel G, Kuehni CE. Health-related quality of life in survivors of childhood cancer: the role

of chronic health problems. Journal of cancer survivorship : research and practice 2013;7:511-22.

515 28. Hernán MA, Hernández-Díaz S, Werler MM, Mitchell AA. Causal knowledge as a
516 prerequisite for confounding evaluation: an application to birth defects epidemiology.
517 American journal of epidemiology 2002;155:176-84.

518 29. Weiss A, Kuonen R, Brockmeier H, Grotzer M, Candreia C, Maire R, Senn P,
519 Stieger C, Rosenfeld J, Veraguth D, Kompis M, Scheinemann K, et al. Audiological
520 monitoring in Swiss childhood cancer patients. Pediatric blood & cancer 2018;65.

30. Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM,
Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, et al.
Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult
cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline
Harmonization Group in collaboration with the PanCare Consortium. The Lancet. Oncology
2019;20:e29-e41.

31. Joo YH, Han KD, Park KH. Association of Hearing Loss and Tinnitus with
Health-Related Quality of Life: The Korea National Health and Nutrition Examination

529 Survey. PloS one 2015;10:e0131247.

- 32. Strebel S, Waespe N, Kuehni CE. Hearing loss in childhood cancer survivors. The
  Lancet. Child & adolescent health 2021;5:e17.
- 33. Nathan PC, Ness KK, Greenberg ML, Hudson M, Wolden S, Davidoff A,
  Laverdiere C, Mertens A, Whitton J, Robison LL, Zeltzer L, Gurney JG. Health-related
  quality of life in adult survivors of childhood Wilms tumor or neuroblastoma: A report from
  the childhood cancer survivor study. Pediatric blood & cancer 2007;49:704-15.

34. Zeltzer LK, Lu Q, Leisenring W, Tsao JC, Recklitis C, Armstrong G, Mertens AC,
Robison LL, Ness KK. Psychosocial outcomes and health-related quality of life in adult
childhood cancer survivors: a report from the childhood cancer survivor study. Cancer
epidemiology, biomarkers & prevention : a publication of the American Association for
Cancer Research, cosponsored by the American Society of Preventive Oncology

- 541 2008;17:435-46.
- 542 35. Weiss A, Sommer G, Kuonen R, Scheinemann K, Grotzer M, Kompis M, Kuehni
  543 CE. Validation of questionnaire-reported hearing with medical records: A report from the
  544 Swiss Childhood Cancer Survivor Study. PloS one 2017;12:e0174479.

545 36. Kuehni CE, Rueegg CS, Michel G, Rebholz CE, Strippoli MP, Niggli FK, Egger
546 M, von der Weid NX. Cohort profile: the Swiss childhood cancer survivor study. International
547 journal of epidemiology 2012;41:1553-64.

548 37. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nature
549 reviews. Cancer 2007;7:573-84.

38. Izuhara K, Wada K, Nakamura K, Tamai Y, Tsuji M, Ito Y, Nagata C. Association
between tinnitus and sleep disorders in the general Japanese population. The Annals of
otology, rhinology, and laryngology 2013;122:701-6.

55339. Bess FH, Hornsby BW. Commentary: listening can be exhausting--fatigue in554children and adults with hearing loss. Ear and hearing 2014;35:592-9.

- 41. Alhanbali S, Dawes P, Lloyd S, Munro KJ. Self-Reported Listening-Related Effort
   and Fatigue in Hearing-Impaired Adults. Ear and hearing 2017;38:e39-e48.
- 560 42. Brinkman TM, Bass JK, Li Z, Ness KK, Gajjar A, Pappo AS, Armstrong GT,
- 561 Merchant TE, Srivastava DK, Robison LL, Hudson MM, Gurney JG. Treatment-induced
- bearing loss and adult social outcomes in survivors of childhood CNS and non-CNS solid
- tumors: Results from the St. Jude Lifetime Cohort Study. Cancer 2015;121:4053-61.
- 43. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT,
  Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, et al.
  Chronic health conditions in adult survivors of childhood cancer. The New England journal of
  medicine 2006;355:1572-82.
- 44. Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, Chemaitilly W, Ehrhardt
  MJ, Bass J, Bishop MW, Shelton K, Lu L, et al. The cumulative burden of surviving
  childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet
- 571 (London, England) 2017;390:2569-82.
- 572 45. Baguley D, McFerran D, Hall D. Tinnitus. Lancet (London, England)
  573 2013;382:1600-7.
- 574

 <sup>40.</sup> Davis H, Schlundt D, Bonnet K, Camarata S, Bess FH, Hornsby B. Understanding
 Listening-Related Fatigue: Perspectives of Adults with Hearing Loss. International journal of
 audiology 2021;60:458-68.

# LEGENDS

Table 1	Demographic and clinical characteristics of study population
Table 2	Association of hearing loss and tinnitus with HRQoL from adjusted linear regression
Table 3	Association of combined auditory complications on HRQoL from adjusted linear regression
Figure 1	Prevalence of self-reported hearing loss at the time of the study
Figure 2	Prevalence of self-reported tinnitus at the time of the study
Figure 3	Spider chart showing norm-based mean scores for all eight health domains and the two summary scores of the SF-36 comparing CCS with and without auditory complications
Supplementary Table S1	Questions on auditory complications from the questionnaires of each participating country translated into English
Supplementary Table S2	Norm-based mean scores from SF-36 comparing CCS with hearing loss and normal hearing
Supplementary Table S3	Norm-based mean scores from SF-36 comparing CCS with and without tinnitus
Supplementary Figure S1	Directed acyclic graph (DAG)

# TABLE 1 Demographic and clinical characteristics of study population

	Total co (N=6,3	
Demographic characteristics	n	(%)
Sex		
Male	2,992	(47)
Female	3,326	(53)
Age at survey (years)	- )	()
25-29.9	2,651	(42)
30-34.9	2,061	(33)
35-39.9	1,074	(17)
40-44	532	(8)
Country of origin	552	(0)
Germany	4,650	(74)
		(74)
Switzerland	822 502	(13)
Czech Republic	592 254	(9)
France	254	(4)
Clinical characteristics	n	(%)
Age at cancer diagnosis (years)		<i>(</i> <b>- -</b> )
0-4.9	1,763	(28)
5-9.9	1,696	(27)
10-18	2,859	(45)
Period of cancer diagnosis		
1974-1984	1,254	(20)
1985-1994	3,488	(55)
1995-2004	1,517	(24)
2005-2009	59	(1)
Time since cancer diagnosis (years)		
5-14.9	592	(9)
15-24.9	3,208	(51)
25-42	2,518	(40)
Cancer diagnosis (ICCC-3)		ì
I Leukemias	2,033	(32)
II Lymphomas	1,466	(23)
III CNS tumours	892	(14)
IV Neuroblastoma	236	(4)
V Retinoblastoma	130	(4) (2)
VI Renal tumours	390	(2) (6)
VI Kenai tumours	28	(<1)
VIII Bone tumours	378	(6)
IX Soft tissue sarcomas	396 240	(6)
X Germ cell tumours	249	(4)
XI Epithelial neoplasms & melanomas	80	(1)
XII Other malignant neoplasms	40	(1)
Subsequent tumour		
Yes	458	(7)
No	5,860	(93)

## **TABLE 1**Continued.

	n	(%)	
<i>Treatments</i> <sup><i>a</i></sup>			
Surgery			
Unknown	863	(14)	
Yes	2,580	(41)	
No	2,875	(46)	
Chemotherapy			
Unknown	603	(10)	
Yes	5,070	(80)	
No	645	(10)	
Radiotherapy			
Unknown	858	(14)	
Yes	3,092	(49)	
No	2,368	(37)	
HSCT			
Unknown	287	(5)	
Yes	151	(2)	
No	5,880	(93)	

Abbreviations: ICCC-3, International Classification of Childhood Cancer-Third Edition; CNS, central nervous

system; HSCT, hematopoietic stem cell transplantation.

<sup>a</sup>Each subject could have had more than one treatment modality.

	Adjusted <sup>a</sup> associa hearing loss		Adjusted <sup>a</sup> associat tinnitus <sup>c</sup>	ion of
Health Domains	Coef. (95%-CI)	$P^{\mathrm{d}}$	Coef. (95%-CI)	$P^{\mathrm{d}}$
Physical Functioning (PF)	-4.5 (-7.7 to -1.4)	0.005	-7.2 (-11.2 to -3.2)	< 0.001
Role Physical (RP)	-2.3 (-4.6 to -0.1)	0.044	-5.9 (-8.8 to -2.9)	< 0.001
Role Emotional (RE)	-2.5 (-5.4 to 0.4)	0.088	-3.9 (-7.0 to -0.8)	0.014
Bodily Pain (BP)	-2.6 (-4.4 to -0.8)	0.004	-5.3 (-7.6 to -3.0)	<0.001
Mental Health (MH)	-2.8 (-4.7 to -0.8)	0.005	-4.2 (-6.9 to -1.6)	0.002
Vitality (VT)	-3.9 (-6.0 to -1.8)	< 0.001	-8.4 (-11.3 to -5.6)	<0.001
General Health (GH)	-4.6 (-6.9 to -2.3)	< 0.001	-8.3 (-11.4 to -5.3)	<0.001
Social Functioning (SF)	-3.8 (-6.3 to -1.3)	0.003	-7.9 (-11.0 to -4.7)	<0.001
Global Summary Scores	Coef. (95%-CI)	$P^{\mathrm{d}}$	Coef. (95%-CI)	$P^{\mathrm{d}}$
PCS	-4.3 (-7.0 to -1.6)	0.002	-8.2 (-11.8 to -4.7)	< 0.001
MCS	-3.2 (-5.5 to -0.8)	0.008	-5.9 (-8.8 to -3.1)	< 0.001

 TABLE 2
 Association of hearing loss and tinnitus with HRQoL from adjusted linear regression analysis

Abbreviations: Coef., estimated beta coefficient from multivariable linear regression; PCS, physical component summary; MCS, mental component summary. <sup>a</sup>Adjusted for: age at survey (continuous, in years); age at cancer diagnosis (continuous, in years); type of cancer diagnosis (according ICCC-3); history of relapse (yes/no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); HSCT (yes, no); country of data provider.

<sup>b</sup>We included the total cohort for analysis of the association of hearing loss on HRQoL (N=6,318).

<sup>c</sup>We included the cohorts from CH, CZ, and FR for analysis of the association of tinnitus on HRQoL (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort.

<sup>d</sup>P-value calculated from Wald test.

	Adjusted <sup>a</sup> associa combined auditory co	
Health Domains	Coef. (95%-CI)	$P^{c}$
Physical Functioning (PF)		0.002
No auditory complications	Reference	
Hearing loss only	-0.1 (-3.3 to 3.1)	
Tinnitus only	-3.3 (-6.6 to 0.1)	
Hearing loss and tinnitus	-15.5 (-24.8 to -6.3)	
Role Physical (RP)		0.002
No auditory complications	Reference	
Hearing loss only	0.1 (-2.5 to 2.7)	
Tinnitus only	-4.5 (-7.5 to -1.4)	
Hearing loss and tinnitus	-8.8 (-15.2 to -2.5)	
Role Emotional (RE)		0.053
No auditory complications	Reference	
Hearing loss only	-2.0 (-6.2 to 2.2)	
Tinnitus only	-4.0 (-7.2 to -0.8)	
Hearing loss and tinnitus	-4.3 (-11.0 to 2.3)	
Bodily Pain (BP)		< 0.001
No auditory complications	Reference	
Hearing loss only	-1.1 (-3.5 to 1.2)	
Tinnitus only	-4.4 (-7.0 to -1.7)	
Hearing loss and tinnitus	-7.6 (-11.7 to -3.5)	
Mental Health (MH)		0.007
No auditory complications	Reference	
Hearing loss only	-2.3 (-5.1 to 0.6)	
Tinnitus only	-4.5 (-7.8 to -1.1)	
Hearing loss and tinnitus	-4.3 (-8.3 to -0.3)	
Vitality (VT)		<0.001
No auditory complications	Reference	
Hearing loss only	-3.0 (-6.1 to 0.1)	
Tinnitus only	-8.7 (-12.2 to -5.2)	
Hearing loss and tinnitus	-8.6 (-13.1 to -4.2)	

**TABLE 3** Association of combined auditory complications on HRQoL from adjusted linear regression analysis

**TABLE 3**Continued.

Health Domains	Coef. (95%-CI)	$P^{c}$
General Health (GH)		< 0.001
No auditory complications	Reference	
Hearing loss only	-2.6 (-6.1 to 0.9)	
Tinnitus only	-7.2 (-11.0 to -3.4)	
Hearing loss and tinnitus	-11.4 (-15.8 to -7.0)	
Social Functioning (SF)		< 0.001
No auditory complications	Reference	
Hearing loss only	-1.6 (-5.0 to 1.8)	
Tinnitus only	-7.0 (-10.4 to -3.6)	
Hearing loss and tinnitus	-10.0 (-16.2 to -3.9)	
Global Summary Scores	Coef. (95%-CI)	$P^{c}$
PCS	\$ * *	< 0.001
No auditory complications	Reference	
Hearing loss only	-0.6 (-3.5 to 2.2)	
Tinnitus only	-5.4 (-8.8 to -1.9)	
Hearing loss and tinnitus	-14.5 (-21.9 to -7.1)	
MCS		< 0.001
No auditory complications	Reference	
Hearing loss only	-2.9 (-6.2 to 0.5)	
Tinnitus only	-6.8 (-10.1 to -3.5)	
Hearing loss and tinnitus	-5.0 (-10.0 to 0.1)	

Abbreviations: PCS, physical component summary; MCS, mental component summary.

<sup>a</sup>Adjusted for: age at survey (continuous, in years); age at cancer diagnosis (continuous, in years); type of cancer diagnosis (according ICCC-3); history of relapse (yes/no); surgery (yes, no); chemotherapy (yes, no); radiotherapy (yes, no); HSCT (yes, no); country of data provider.

<sup>b</sup>We included the cohorts from CH, CZ, and FR for the analysis (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort.

<sup>c</sup>*P*-value calculated from Wald test.




FIGURE 1 Prevalence of self-reported hearing loss at the time of the study (N=6,318). *P*-values are calculated from chi<sup>2</sup>-statistics comparing prevalence between survivors of leukemia with survivors of other tumor types. Abbreviations: CNS, central nervous system.





FIGURE 2 Prevalence of self-reported tinnitus at the time of the study (N=1,668). Data from the cohorts of CH, CZ, and FR are shown. No data on tinnitus was available for the German cohort (n=4,650).

P-values are calculated from chi<sup>2</sup>-statistics comparing prevalence between survivors of leukemia with survivors of other tumor types.

Abbreviations: CNS, central nervous system.



**FIGURE 3** The two spider charts (A, B) show norm-based mean scores for all eight health domains and the two summary scores of the SF-36 comparing [A] CCS with hearing loss and normal hearing (N=6,318) and [B] CCS with tinnitus only, tinnitus and hearing loss, and without tinnitus (N=1,668). We included the cohorts from CH, CZ, and FR for the analysis of the association of tinnitus on HRQoL [B] (N=1,668) but excluded the cohort from Germany (n=4,650) because no data on tinnitus was available for the German cohort

Higher scores indicate better HRQoL. Normal population (shown as dashed line) has an estimated mean score of 50 with a standard deviation of 10 for all HRQoL scores of the SF-36. Raw data of the figure are shown in the supplement (Supplement Table S2, S3).

Abbreviations: PF, physical functioning; RP, role physical; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health; PCS, physical component summary; MCS, mental component summary.